Inspired by a convo w/ @IanRountree:
Hard to compete in some areas of bio w/ funds like Flagship or Atlas bc once something's working in the lab, their reach in tech transfer offices is so strong that they'll scoop it up. Feels like there's a corollary in OSS and Series A funds
-
-
also this reminds me,
@IanRountree-- biotech fort with@shaklakhani and I soon? - Show replies
New conversation
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
